Condition
Resectable Hepatocellular Carcinoma With High Risk of Recurrence clinical trials and research
Research outlook What's coming for Liver cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 3 Resectable Hepatocellular Carcinoma With High Risk of Recurrence clinical trials that are recruiting, in China. By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 3Clinical trials
- 1Country
Newest Resectable Hepatocellular Carcinoma With High Risk of Recurrence clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Neoadjuvant TACE plus atezolizumab and bevacizumab for resectable high-risk liver cancer | Phase 2 | Beijing, Beijing Municipality and 3 other locations | Recruiting | Nov 20, 2025 |
| AK104 plus TACE with surgery for resectable high‑risk liver cancer (real‑world cohort) | — | Guangzhou, Guangdong | Recruiting | Jul 15, 2025 |
| Neoadjuvant iparomlimab and tuvonralimab before surgery for resectable hepatocellular carcinoma | Phase 2 | Wuhan, Hubei | Recruiting | May 1, 2025 |
All recruiting trials (3)
-
Neoadjuvant TACE plus atezolizumab and bevacizumab for resectable high-risk liver cancer
This study will try combining TACE with atezolizumab and bevacizumab before surgery to see if it shrinks tumors and reduces the chance of recurrence for people with resectable hepatocellular carcinoma who are at high risk of coming back.
-
AK104 plus TACE with surgery for resectable high‑risk liver cancer (real‑world cohort)
This project follows people with resectable, high‑risk hepatocellular carcinoma who have surgery without neoadjuvant AK104 plus TACE to compare their outcomes with patients who received the neoadjuvant approach.
-
Neoadjuvant iparomlimab and tuvonralimab before surgery for resectable hepatocellular carcinoma
This study tests whether giving iparomlimab and tuvonralimab before surgery, then after surgery, can help prevent cancer from coming back in people with resectable liver cancer at high risk of recurrence.
Related topics
Quick answers
How many Resectable Hepatocellular Carcinoma With High Risk of Recurrence clinical trials are recruiting right now?
3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.